palbociclib

drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer

Uses your system voice; voice and rate in settings.

Q15269707Snapshot

≈ 3 min read

Names in other languages

  • العربيةبالبوسيكليب
  • DeutschPalbociclib
  • Englishpalbociclib
  • Françaispalbociclib
  • nnpalbociklib
  • shPalbociklib
  • СрпскиPalbociklib
  • 中文帕布昔利布

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Palbociclib, sold under the brand name Ibrance among others, is an anti-cancer medication used for the treatment of HR-positive and HER2-negative breast cancer. It was developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.

Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy. The most common side effects include neutropenia (low blood levels of neutrophils, a type of white blood cell that fights infection), infections, leucopenia (low white blood cell counts), tiredness, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), anemia (low red blood cell counts), diarrhea, alopecia (hair loss), and thrombocytopenia (low blood platelet counts).

The most common severe side effects include neutropenia, leucopenia, infections, anemia, tiredness, and increased blood levels of liver enzymes (aspartate and alanine transaminases).

Mechanism of action

It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with Cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division.

Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.

HR+ breast cancer

The PALOMA-3 trial announced in April 2015 that the addition of palbociclib was superior to fulvestrant alone for progression-free survival. In the phase II PALOMA-1 trial reported at the April 2014 annual meeting of the American Association for Cancer Research, the addition of palbociclib to letrozole was shown to significantly slow the progression of advanced cancer (median progression-free survival increased from 10.2 months to 20.2 months), but was not shown to have a statistically significant effect on increasing patients' overall survival times.

Pfizer announce on May 31, 2020, the results of a preplanned efficacy and futility analysis. The results indicate that, when used in combination with post-surgery endocrine therapy, it "is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS)."

The trial was conducted on male and female patients with HR-positive, HER2-negative early stage breast cancer.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1363754282 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.